Biotech | May 01, 2022
Inmagene receives USFDA's IND clearance for ox40 antagonist
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases
It is expanding the diagnostics business footprint in North East India
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Subscribe To Our Newsletter & Stay Updated
